EA201792407A2 - Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения - Google Patents
Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их примененияInfo
- Publication number
- EA201792407A2 EA201792407A2 EA201792407A EA201792407A EA201792407A2 EA 201792407 A2 EA201792407 A2 EA 201792407A2 EA 201792407 A EA201792407 A EA 201792407A EA 201792407 A EA201792407 A EA 201792407A EA 201792407 A2 EA201792407 A2 EA 201792407A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- containing buffer
- compositions containing
- compositions
- vaccines
- ways
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее изобретение относится к парентеральным композициям вакцины однократной дозы, содержащим смеси моновалентных вирусоподобных частиц норовируса. Также раскрыты способы обеспечения защитного иммунитета к норовирусным инфекциям у субъектов, являющихся людьми, посредством введения таких композиций.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506447P | 2011-07-11 | 2011-07-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201792407A2 true EA201792407A2 (ru) | 2018-03-30 |
EA201792407A3 EA201792407A3 (ru) | 2018-07-31 |
EA035442B1 EA035442B1 (ru) | 2020-06-17 |
Family
ID=47506489
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201490258A EA029470B1 (ru) | 2011-07-11 | 2012-07-11 | Способ стимулирования формирования защитного иммунитета против норовируса |
EA201792407A EA035442B1 (ru) | 2011-07-11 | 2012-07-11 | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
EA202090699A EA202090699A3 (ru) | 2011-07-11 | 2012-07-11 | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201490258A EA029470B1 (ru) | 2011-07-11 | 2012-07-11 | Способ стимулирования формирования защитного иммунитета против норовируса |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090699A EA202090699A3 (ru) | 2011-07-11 | 2012-07-11 | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
Country Status (29)
Country | Link |
---|---|
US (5) | US9801934B2 (ru) |
EP (3) | EP3299030B1 (ru) |
JP (2) | JP6208659B2 (ru) |
KR (1) | KR102096937B1 (ru) |
CN (3) | CN103874507A (ru) |
AU (2) | AU2012282658B2 (ru) |
BR (1) | BR112014000656A2 (ru) |
CA (1) | CA2841356C (ru) |
CL (1) | CL2014000082A1 (ru) |
CR (2) | CR20190540A (ru) |
DK (1) | DK3299030T3 (ru) |
DO (2) | DOP2014000004A (ru) |
EA (3) | EA029470B1 (ru) |
EC (1) | ECSP14013201A (ru) |
ES (2) | ES2656527T3 (ru) |
GE (1) | GEP201706668B (ru) |
HK (3) | HK1198136A1 (ru) |
IL (1) | IL230356B (ru) |
MA (1) | MA35414B1 (ru) |
MX (1) | MX356586B (ru) |
MY (1) | MY170746A (ru) |
PE (1) | PE20140845A1 (ru) |
PH (1) | PH12018501515B1 (ru) |
PL (2) | PL3299030T3 (ru) |
SG (1) | SG10201605644WA (ru) |
TN (1) | TN2014000008A1 (ru) |
UA (1) | UA117732C2 (ru) |
WO (1) | WO2013009849A1 (ru) |
ZA (2) | ZA201401012B (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7955603B2 (en) | 2006-09-29 | 2011-06-07 | Ligocyte Pharmaceuticals, Inc. | Norovirus vaccine formulations |
CN104740624B (zh) | 2007-09-18 | 2018-04-24 | 武田疫苗股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
ES2656527T3 (es) | 2011-07-11 | 2018-02-27 | Takeda Vaccines, Inc. | Formulaciones parenterales de vacunas de norovirus |
JP2016533172A (ja) | 2013-10-03 | 2016-10-27 | タケダ ワクチン,インコーポレイテッド | 細胞株からラブドウイルスを検出および除去する方法 |
WO2015093452A1 (ja) | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
CN107184970A (zh) * | 2017-02-16 | 2017-09-22 | 北京生物制品研究所有限责任公司 | 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途 |
GB201703644D0 (en) | 2017-03-07 | 2017-04-19 | Elopak As | Improvements in or relating to toller mounting arrangements |
JP2020519666A (ja) * | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
JP2021514391A (ja) * | 2018-02-15 | 2021-06-10 | アイコン ジェネティクス ゲーエムベーハー | ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン |
WO2019231712A1 (en) * | 2018-05-29 | 2019-12-05 | Stc.Unm | Virus-like particle compositions and methods of using same |
CN109265542B (zh) * | 2018-09-27 | 2021-06-15 | 国药中生生物技术研究院有限公司 | 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用 |
AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
US20230285534A1 (en) * | 2020-01-08 | 2023-09-14 | Bharat Biotech International Limited | Viral vaccine compositions and methods of preparations thereof |
AU2022248473A1 (en) | 2021-03-29 | 2023-10-26 | Denka Company Limited | Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus |
JP2024519800A (ja) | 2021-05-21 | 2024-05-21 | タケダ ワクチン,インコーポレイテッド | 固体組成物、フリーズドライ方法およびガラスバイアル |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6572862B1 (en) | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
AU1893592A (en) | 1991-03-25 | 1992-10-21 | Board Of Trustees Of The Leland Stanford Junior University | Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas |
JPH07509122A (ja) | 1992-04-08 | 1995-10-12 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ,アズ レプリゼンテッド バイ ザ セクレター,デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 野生型麻疹ウイルス糖タンパク質:ワクチンおよびその検出方法 |
JPH08500250A (ja) | 1992-09-07 | 1996-01-16 | ベイラー・カレッジ・オブ・メディシン | ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬 |
WO1994021292A1 (en) | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
US5788970A (en) | 1994-03-29 | 1998-08-04 | The University Of Maryland College Park | Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon |
HUT76354A (en) | 1994-05-16 | 1997-08-28 | Merck & Co Inc | Papillomavirus vaccines |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5861241A (en) | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US5834015A (en) * | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
US5953727A (en) | 1996-10-10 | 1999-09-14 | Incyte Pharmaceuticals, Inc. | Project-based full-length biomolecular sequence database |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
JP4598201B2 (ja) | 1997-04-08 | 2010-12-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 安定化ヒトパピローマウイルス製剤 |
WO1998050071A1 (en) | 1997-05-01 | 1998-11-12 | Chiron Corporation | Use of virus-like particles as adjuvants |
US20040265377A1 (en) | 1997-10-27 | 2004-12-30 | Harry Seager | Solid dispersing vaccine composition for oral delivery |
ATE324436T1 (de) | 1998-08-14 | 2006-05-15 | Merck & Co Inc | Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln. |
WO2000035479A1 (en) | 1998-12-17 | 2000-06-22 | Merck & Co., Inc. | Synthetic virus-like particles with heterologous epitopes |
PT1150712E (pt) * | 1999-02-05 | 2008-12-22 | Merck & Co Inc | Formulações para a vacina do vírus do papiloma humano |
WO2000079280A1 (fr) | 1999-06-22 | 2000-12-28 | Japan As Represented By Director-General National Institute Of Infectious Diseases | Materiel de detection de srsv |
JP2002020399A (ja) | 2000-07-10 | 2002-01-23 | Osaka Prefecture | ノルウォークウイルス(nv)を認識するモノクローナル抗体 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
WO2003068804A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Novel insect cell line |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
WO2003087327A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
AU2003237528A1 (en) | 2002-06-07 | 2003-12-22 | Kentucky Bioprocessing, Llc | Flexible vaccine assembly and vaccine delivery platform |
DE60335186D1 (de) | 2002-06-20 | 2011-01-13 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
US20050106178A1 (en) | 2003-01-30 | 2005-05-19 | Chiron Corporation | Adjuvanted influenza vaccine |
WO2004073652A2 (en) | 2003-02-20 | 2004-09-02 | Becton Dickinson And Company | Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
WO2005030806A2 (en) | 2003-09-24 | 2005-04-07 | Montana State University | Norovirus monoclonal antibodies and peptides |
WO2005037223A2 (en) | 2003-10-15 | 2005-04-28 | Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
US20050260225A1 (en) | 2004-05-18 | 2005-11-24 | Goldberg Joanna B | Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
EP1809325B1 (en) | 2004-10-20 | 2013-11-20 | Sanofi Pasteur Biologics, LLC | Vaccines against japanese encephalitis virus |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
AU2006203985A1 (en) | 2005-01-05 | 2006-07-13 | Philadelphia Health And Education Corporation | Delivery vehicles, bioactive substances and viral vaccines |
US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
CA2598488A1 (en) | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics, Inc. | Immunogens from uropathogenic escherichia coli |
CN103203016A (zh) | 2005-03-18 | 2013-07-17 | 赛托斯生物技术公司 | 猫变应原融合蛋白及其用途 |
JP2009501001A (ja) | 2005-06-01 | 2009-01-15 | ダウ グローバル テクノロジーズ インコーポレイティド | 多価ウイルス様粒子の製造 |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
JP2007145775A (ja) | 2005-11-29 | 2007-06-14 | Falco Life Science:Kk | ノロウイルスgiの高感度検出方法 |
US20080029915A1 (en) * | 2006-08-02 | 2008-02-07 | Courtoy Nv | Rotary tablet press |
US7955603B2 (en) | 2006-09-29 | 2011-06-07 | Ligocyte Pharmaceuticals, Inc. | Norovirus vaccine formulations |
NZ577405A (en) | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
SG179488A1 (en) * | 2007-03-14 | 2012-04-27 | Ligocyte Pharmaceuticals Inc | Virus like particle purification |
US8648229B2 (en) | 2007-09-12 | 2014-02-11 | Australian Centre For Plant Functional Genomics Pty Ltd | Plant seed active transcriptional control sequences |
CN104740624B (zh) * | 2007-09-18 | 2018-04-24 | 武田疫苗股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
US20100266636A1 (en) * | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
WO2010017542A1 (en) | 2008-08-08 | 2010-02-11 | Ligocyte Pharmaceuticals, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
EP2381959A1 (en) * | 2009-01-22 | 2011-11-02 | Pharmathene Inc. | Stable vaccine compositions and methods of use |
EP2942062A1 (en) * | 2009-02-10 | 2015-11-11 | Novartis AG | Influenza vaccine regimens for pandemic-associated strains |
US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
JP2013517773A (ja) | 2010-01-21 | 2013-05-20 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
EP3388081A1 (en) * | 2010-05-26 | 2018-10-17 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
ES2656527T3 (es) | 2011-07-11 | 2018-02-27 | Takeda Vaccines, Inc. | Formulaciones parenterales de vacunas de norovirus |
JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
FI3827838T3 (fi) | 2015-12-16 | 2023-06-19 | Walter & Eliza Hall Inst Medical Res | Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa |
GB2605540B (en) | 2016-10-18 | 2022-12-21 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
SG11202010763VA (en) | 2018-05-03 | 2020-11-27 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
US20210308249A1 (en) | 2018-08-20 | 2021-10-07 | Takeda Vaccines, Inc. | Vlp formulations |
AR117462A1 (es) | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
SG11202108644UA (en) | 2019-02-15 | 2021-09-29 | Editas Medicine Inc | Modified natural killer (nk) cells for immunotherapy |
-
2012
- 2012-07-11 ES ES12811916.1T patent/ES2656527T3/es active Active
- 2012-07-11 WO PCT/US2012/046222 patent/WO2013009849A1/en active Application Filing
- 2012-07-11 ES ES17199372T patent/ES2926487T3/es active Active
- 2012-07-11 CA CA2841356A patent/CA2841356C/en active Active
- 2012-07-11 CR CR20190540A patent/CR20190540A/es unknown
- 2012-07-11 PL PL17199372.8T patent/PL3299030T3/pl unknown
- 2012-07-11 EA EA201490258A patent/EA029470B1/ru not_active IP Right Cessation
- 2012-07-11 KR KR1020147003571A patent/KR102096937B1/ko active IP Right Grant
- 2012-07-11 EP EP17199372.8A patent/EP3299030B1/en active Active
- 2012-07-11 PE PE2014000054A patent/PE20140845A1/es active IP Right Grant
- 2012-07-11 EA EA201792407A patent/EA035442B1/ru not_active IP Right Cessation
- 2012-07-11 AU AU2012282658A patent/AU2012282658B2/en active Active
- 2012-07-11 MX MX2014000411A patent/MX356586B/es active IP Right Grant
- 2012-07-11 EP EP22176978.9A patent/EP4112074A1/en active Pending
- 2012-07-11 CN CN201280043691.2A patent/CN103874507A/zh active Pending
- 2012-07-11 CN CN201510262891.2A patent/CN105031637A/zh active Pending
- 2012-07-11 GE GEAP201213384A patent/GEP201706668B/en unknown
- 2012-07-11 EP EP12811916.1A patent/EP2731621B1/en active Active
- 2012-07-11 EA EA202090699A patent/EA202090699A3/ru unknown
- 2012-07-11 BR BR112014000656A patent/BR112014000656A2/pt not_active Application Discontinuation
- 2012-07-11 MY MYPI2014000073A patent/MY170746A/en unknown
- 2012-07-11 PL PL12811916T patent/PL2731621T3/pl unknown
- 2012-07-11 CN CN201810373895.1A patent/CN108567975A/zh active Pending
- 2012-07-11 SG SG10201605644WA patent/SG10201605644WA/en unknown
- 2012-07-11 DK DK17199372.8T patent/DK3299030T3/da active
- 2012-07-11 JP JP2014520273A patent/JP6208659B2/ja active Active
- 2012-11-07 UA UAA201401321A patent/UA117732C2/uk unknown
-
2013
- 2013-03-15 US US13/840,403 patent/US9801934B2/en active Active
-
2014
- 2014-01-07 TN TNP2014000008A patent/TN2014000008A1/en unknown
- 2014-01-07 IL IL230356A patent/IL230356B/en active IP Right Grant
- 2014-01-10 DO DO2014000004A patent/DOP2014000004A/es unknown
- 2014-01-10 CL CL2014000082A patent/CL2014000082A1/es unknown
- 2014-02-06 MA MA36741A patent/MA35414B1/fr unknown
- 2014-02-10 ZA ZA2014/01012A patent/ZA201401012B/en unknown
- 2014-02-11 CR CR20140069A patent/CR20140069A/es unknown
- 2014-02-11 EC ECSP14013201 patent/ECSP14013201A/es unknown
- 2014-11-21 HK HK14111772.5A patent/HK1198136A1/xx unknown
- 2014-12-18 HK HK14112697.5A patent/HK1199202A1/xx unknown
- 2014-12-18 HK HK16102061.2A patent/HK1215154A1/zh unknown
-
2015
- 2015-02-09 ZA ZA2015/00915A patent/ZA201500915B/en unknown
- 2015-02-19 AU AU2015200836A patent/AU2015200836B2/en active Active
- 2015-07-10 US US14/796,614 patent/US9867876B2/en active Active
-
2017
- 2017-05-02 JP JP2017091755A patent/JP6613259B2/ja active Active
- 2017-12-08 US US15/836,030 patent/US10675341B2/en active Active
-
2018
- 2018-07-06 PH PH12018501515A patent/PH12018501515B1/en unknown
-
2020
- 2020-06-05 US US16/894,291 patent/US11701420B2/en active Active
-
2022
- 2022-02-04 DO DO2022000030A patent/DOP2022000030A/es unknown
-
2023
- 2023-05-24 US US18/322,679 patent/US20230338503A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792407A3 (ru) | Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения | |
MX2018007627A (es) | Vacuna contra el virus del zika. | |
EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
MX2016003419A (es) | Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico. | |
EA202090547A3 (ru) | Макроциклические деаза-оксипурины для лечения вирусных инфекций | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
NZ711946A (en) | Newcastle disease viruses and uses thereof | |
EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
EA201491548A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
MY168959A (en) | Vaccine compositions for the prevention of dengue virus infection | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
PH12014502875A1 (en) | Vaccine compositions for prevention against dengue virus infection | |
EA201590491A1 (ru) | Иммуногенная композиция | |
MX2014004814A (es) | Compuestos y metodos para mejorar las respuestas inmunes innatas. | |
MX2013013801A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
UA114298C2 (uk) | Пептид торк та вакцина, що його містить | |
MX2016000107A (es) | Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria. | |
MX364946B (es) | Sistema adyuvante mejorado para la administración de vacunas orales. | |
EA201592242A1 (ru) | Производные пиридона для лечения вирусных инфекций и других заболеваний | |
EA201690378A1 (ru) | Вакцинные композиции против наркотической зависимости | |
UA106111C2 (ru) | Способ получения человеческого интерферона с использованием наночастиц оксида церия |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |